Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes
EUGenMed… - European heart …, 2016 - academic.oup.com
In the vast majority of cardiovascular diseases (CVDs), there are well-described differences
between women and men in epidemiology, pathophysiology, clinical manifestations, effects …
between women and men in epidemiology, pathophysiology, clinical manifestations, effects …
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential
Left ventricular hypertrophy is a leading risk factor for cardiovascular morbidity and mortality.
Although reverse ventricular remodelling was long thought to be irreversible, evidence from …
Although reverse ventricular remodelling was long thought to be irreversible, evidence from …
Evolution and prognostic impact of cardiac damage after aortic valve replacement
Background The impact of aortic valve replacement (AVR) on progression/regression of
extravalvular cardiac damage and its association with subsequent prognosis is unknown …
extravalvular cardiac damage and its association with subsequent prognosis is unknown …
Medical treatment of aortic stenosis
Untreated, severe, symptomatic aortic stenosis is associated with a dismal prognosis. The
only treatment shown to improve survival is aortic valve replacement; however, before …
only treatment shown to improve survival is aortic valve replacement; however, before …
Sex-based differences in outcomes with transcatheter aortic valve therapy: TVT registry from 2011 to 2014
Background: A differential impact of sex has been observed in transcatheter aortic valve
replacement (TAVR) outcomes from small observational studies and subgroup analyses of …
replacement (TAVR) outcomes from small observational studies and subgroup analyses of …
Reverse myocardial remodeling following valve replacement in patients with aortic stenosis
Background: Left ventricular (LV) hypertrophy, a key process in human cardiac disease,
results from cellular (hypertrophy) and extracellular matrix expansion (interstitial fibrosis) …
results from cellular (hypertrophy) and extracellular matrix expansion (interstitial fibrosis) …
Regression of left ventricular mass after transcatheter aortic valve replacement: the PARTNER trials and registries
Background Greater early left ventricular mass index (LVMi) regression is associated with
fewer hospitalizations 1 year after transcatheter aortic valve replacement (TAVR). The …
fewer hospitalizations 1 year after transcatheter aortic valve replacement (TAVR). The …
Incidence, causes, and predictors of early (≤ 30 days) and late unplanned hospital readmissions after transcatheter aortic valve replacement
L Nombela-Franco, M Trigo, G Morrison-Polo… - JACC: Cardiovascular …, 2015 - jacc.org
Objectives: The aim of this study was to determine the incidence, causes, and predictors of
unplanned hospital readmissions after transcatheter aortic valve replacement (TAVR) …
unplanned hospital readmissions after transcatheter aortic valve replacement (TAVR) …
Long-term valve performance of TAVR and SAVR: a report from the PARTNER I trial
Objectives: The aim of this study was to evaluate the long-term performance of transcatheter
aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) through …
aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) through …
Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement
Importance Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor
prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS …
prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS …